U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H32O2
Molecular Weight 340.499
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEDROGESTONE

SMILES

[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C=C(C)C4=CC(=O)CC[C@]34C

InChI

InChIKey=HCFSGRMEEXUOSS-JXEXPEPMSA-N
InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.cngof.asso.fr/d_livres/1996_GO_157_laurent.pdf

Medrogestone is a progesterone derivative used for the treatment of progesterone deficiency, especially those observed in the premenopausal period, haemorrhages and menorrhagia of fibroids, endometriosis, menstrual cycle disorders, etc. The drug acts by binding and activating progesterone receptors. In Europe, medrogestone is available under the name Colprone, however it is no longer marketed in the USA, Germany and Austria.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
COLPRONE

Approved Use

Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Primary
Approved
8429
COLPRONE

Approved Use

Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Palliative
Approved
8429
COLPRONE

Approved Use

Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Primary
Approved
8429
COLPRONE

Approved Use

Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Primary
Approved
8429
COLPRONE

Approved Use

Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
PubMed

PubMed

TitleDatePubMed
Biological effects of progestins in breast cancer.
2001 Dec
Cyclic progestin therapy for the management of mastopathy and mastodynia.
2001 Dec
Effects of estrogen/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control.
2001 Feb
The selective estrogen enzyme modulator (SEEM) in breast cancer.
2001 Jan-Mar
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
2001 May
Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone.
2002 Dec 10
Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen.
2002 Feb 26
Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women.
2002 Feb 26
[Tibolone].
2002 Sep 7
Differential effects of progestins on breast tissue enzymes.
2003 Dec 10
Androgens and antiandrogens.
2003 Nov
The selective estrogen enzyme modulators in breast cancer: a review.
2004 Jun 7
Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
2005 Feb
Influence of different HRT regimens on mammographic density.
2005 Feb 14
Age-related cognitive decline in the menopause: effects of hormone replacement therapy on cognitive event-related potentials.
2005 Jul 16
Effects of hormone replacement therapy on the main fatty acids of serum and phospholipids of postmenopausal women.
2005 Nov-Dec
Breast cancer risk associated with different HRT formulations: a register-based case-control study.
2006 Sep 12
Oral progestagens before menopause and breast cancer risk.
2007 Mar 12
Colon cancer risk and different HRT formulations: a case-control study.
2007 May 8
Progestins and breast cancer.
2007 Oct
Free synthetic and natural estrogen hormones in influent and effluent of three municipal wastewater treatment plants.
2007 Sep
Correlation of estrogen sulfotransferase activity and proliferation in normal and carcinomatous human breast. A hypothesis.
2007 Sep-Oct
Progestins in the menopause in healthy women and breast cancer patients.
2009 Apr 20
Breast cancer and steroid metabolizing enzymes: the role of progestogens.
2009 Dec
Estrogen sulfotransferases in breast and endometrial cancers.
2009 Feb
Presence of steroid hormones and antibiotics in surface water of agricultural, suburban and mixed-use areas.
2009 Jul
Patents

Patents

US5519153 A
1

Sample Use Guides

In Vivo Use Guide
Take two tablets (10 mg) per day.
Route of Administration: Oral
In Vitro Use Guide
T-47D cells were incubated with medrogestone for 24h and the drug inhibited 17beta-hydroxysteroid dehydrogenase activity in a dose-dependent manner by 39% and 80% at 5 x 10(-8) M and 5 x 10(-5) M.
Name Type Language
MEDROGESTONE
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
MEDROGESTONE [USAN]
Common Name English
NSC-123018
Code English
MEDROGESTONE [MI]
Common Name English
AY-13615
Code English
COLPRO
Brand Name English
PREGNA-4,6-DIENE-3,20-DIONE, 6,17-DIMETHYL-
Systematic Name English
AY-62022
Code English
METROGESTONE
Common Name English
AY 62022
Code English
PROTHIL
Brand Name English
AY-13615S
Code English
MEDROGESTERONE
Common Name English
medrogestone [INN]
Common Name English
6,17-Dimethylpregna-4,6-diene-3,20-dione
Systematic Name English
Medrogestone [WHO-DD]
Common Name English
COLPRONE
Brand Name English
ETOGYN
Brand Name English
MEDROGESTONE [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC G03DB03
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
NCI_THESAURUS C776
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
WHO-VATC QG03FB07
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
WHO-ATC G03FB07
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
WHO-VATC QG03DB03
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
Code System Code Type Description
DRUG BANK
DB09124
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
RXCUI
6690
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY RxNorm
WIKIPEDIA
Medrogestone
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
CAS
977-79-7
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
MESH
D008524
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
SMS_ID
100000091988
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
INN
1852
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
MERCK INDEX
m7132
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2106825
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
PUBCHEM
9949848
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
NCI_THESAURUS
C90970
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID70878637
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
DRUG CENTRAL
1657
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
ECHA (EC/EINECS)
213-555-0
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
NSC
123018
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
EVMPD
SUB08696MIG
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
FDA UNII
077DN93G5B
Created by admin on Sat Dec 16 17:24:52 GMT 2023 , Edited by admin on Sat Dec 16 17:24:52 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of MEDROGESTONE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966